Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEART: Anastrozole vs Tamoxifen Hepatotoxicity in Breast Cancer
NCT00537771Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2007
- Primary completion
- Dec 2011
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of anastrozole in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Incidence of Fatty Liver Disease at 144 weeks. Started Sep 2007; status: completed.
02
Drugs
anastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00537771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537771.